Giovanni Zanotti

465 total citations
36 papers, 349 citations indexed

About

Giovanni Zanotti is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Economics and Econometrics. According to data from OpenAlex, Giovanni Zanotti has authored 36 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 10 papers in Economics and Econometrics. Recurrent topics in Giovanni Zanotti's work include Renal cell carcinoma treatment (16 papers), Advanced Breast Cancer Therapies (9 papers) and Cancer Treatment and Pharmacology (9 papers). Giovanni Zanotti is often cited by papers focused on Renal cell carcinoma treatment (16 papers), Advanced Breast Cancer Therapies (9 papers) and Cancer Treatment and Pharmacology (9 papers). Giovanni Zanotti collaborates with scholars based in United States, Canada and United Kingdom. Giovanni Zanotti's co-authors include Raymond Farkouh, Cheryl McDade, Stephanie Earnshaw, David Strutton, James A. Kaye, Samantha K. Kurosky, Frede Donskov, Jonathan Kish, Ruslan Horblyuk and Debanjali Mitra and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Giovanni Zanotti

35 papers receiving 344 citations

Peers

Giovanni Zanotti
Michael B. Osswald United States
Bakarou Kamaté Mali
Ann G. Schwartz United States
Mingjia Li United States
Shridevi Subramaniam Malaysia
Melissa Pavilack United States
Sonal S. Noticewala United States
Alireza Mousavi-Jarrahi Iran
Mathieu Robain France
Sheema Hassan Pakistan
Michael B. Osswald United States
Giovanni Zanotti
Citations per year, relative to Giovanni Zanotti Giovanni Zanotti (= 1×) peers Michael B. Osswald

Countries citing papers authored by Giovanni Zanotti

Since Specialization
Citations

This map shows the geographic impact of Giovanni Zanotti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giovanni Zanotti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giovanni Zanotti more than expected).

Fields of papers citing papers by Giovanni Zanotti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giovanni Zanotti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giovanni Zanotti. The network helps show where Giovanni Zanotti may publish in the future.

Co-authorship network of co-authors of Giovanni Zanotti

This figure shows the co-authorship network connecting the top 25 collaborators of Giovanni Zanotti. A scholar is included among the top collaborators of Giovanni Zanotti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giovanni Zanotti. Giovanni Zanotti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Zakharia, Yousef, Despina Thomaidou, Benjamin Li, et al.. (2022). Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States. Frontiers in Oncology. 12. 861189–861189. 10 indexed citations
4.
Bentley, Sarah, Chloe Johnson, Elaine Brohan, et al.. (2020). Improving patient-clinician communication following nephrectomy in renal cell carcinoma: Development, content validation and pilot testing of a conversation aid tool. Patient Education and Counseling. 104(1). 99–108. 1 indexed citations
5.
Wells, J. Connor, Jeffrey Graham, Benoit Beuselinck, et al.. (2019). Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 18(4). e350–e359. 2 indexed citations
6.
Graham, Jeffrey, Amishi Y. Shah, J. Connor Wells, et al.. (2019). Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. European Urology Oncology. 4(1). 102–111. 30 indexed citations
7.
Staehler, Michael, Robert J. Motzer, Daniel J. George, et al.. (2018). Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. Annals of Oncology. 29(10). 2098–2104. 32 indexed citations
8.
Zanotti, Giovanni, Mihaela Mates, Julie Lemieux, et al.. (2018). Real-World Patient- and Caregiver-reported Outcomes in Advanced Breast Cancer. Current Oncology. 25(4). 282–290. 13 indexed citations
9.
Kurosky, Samantha K., Debanjali Mitra, Giovanni Zanotti, & James A. Kaye. (2017). Treatment Patterns and Outcomes of Patients With Metastatic ER+/HER-2− Breast Cancer: A Multicountry Retrospective Medical Record Review. Clinical Breast Cancer. 18(4). e529–e538. 19 indexed citations
10.
11.
Zanotti, Giovanni, Ritesh Banerjee, Mihaela Mates, et al.. (2016). A Real-World Outcome Research Study On Quality of Life, Work Productivity And Healthcare Resource Utilization In Metastatic Breast Cancer For Patients And Caregivers. Value in Health. 19(7). A616–A616. 2 indexed citations
12.
13.
Zanotti, Giovanni, et al.. (2016). Treatment and Patient Burden in ER+ HER2- Metastatic Breast Cancer: Results From a Physician Survey in the United States. Value in Health. 19(3). A171–A171. 1 indexed citations
14.
Burton, Tanya, Stacey DaCosta Byfield, Gregory L. Smith, et al.. (2016). Clinical and economic outcomes by first-line treatment among women with HR+/HER2– metastatic breast cancer in a large US health plan database. Current Medical Research and Opinion. 32(8). 1417–1423. 12 indexed citations
15.
Kurosky, Samantha K., Debanjali Mitra, Giovanni Zanotti, & James A. Kaye. (2015). Patient Characteristics And Treatment Patterns In Er+/Her2- Metastatic Breast Cancer In The Uk: Results From A Retrospective Medical Record Review. Value in Health. 18(7). A492–A492. 2 indexed citations
16.
Chuck, Anderson, et al.. (2012). PIN33 Pharmacoeconomic Evaluation of 13-Valent Pneumococcal Conjugate and 23-Valent Pneumococcal Polysaccharide Vaccine in Canadian Adults. Value in Health. 15(4). A243–A243. 1 indexed citations
17.
Earnshaw, Stephanie, Cheryl McDade, Giovanni Zanotti, Raymond Farkouh, & David Strutton. (2012). Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infectious Diseases. 12(1). 101–101. 46 indexed citations
18.
Thirion, Daniel J. G., et al.. (2012). Cost Comparison of Linezolid Versus Vancomycin for Treatment of Complicated Skin and Skin‐Structure Infection Caused by Methicillin‐Resistant Staphylococcus aureus in Quebec. Canadian Journal of Infectious Diseases and Medical Microbiology. 23(4). 187–195. 5 indexed citations
19.
Vergnenègre, A., Egbert F. Smit, Bárbara Parente, et al.. (2012). Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study. Current Medical Research and Opinion. 28(8). 1253–1262. 9 indexed citations
20.
Zanotti, Giovanni. (1954). VI Aspects of Hearing Physio-Pathology during the First Postoperative Period following Fenestration. Annals of Otology Rhinology & Laryngology. 63(1). 69–80. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael B. Osswald Breakdown of academic impact, for papers by Bakarou Kamaté Breakdown of academic impact, for papers by Ann G. Schwartz Breakdown of academic impact, for papers by Mingjia Li Breakdown of academic impact, for papers by Shridevi Subramaniam Breakdown of academic impact, for papers by Melissa Pavilack Breakdown of academic impact, for papers by Sonal S. Noticewala Breakdown of academic impact, for papers by Alireza Mousavi-Jarrahi Breakdown of academic impact, for papers by Mathieu Robain Breakdown of academic impact, for papers by Sheema Hassan
Rankless by CCL
2026